AbbVie ’s Maviret receives Japanese MHLW approval to treat HCV

The Japanese Ministry of Health, Labour and Welfare (MHLW) has approved AbbVie ’s Maviret (glecaprevir / pibrentasvir) to treat adults with chronic hepatitis C virus (HCV) infection across genotypes 1 to 6 (GT1-6).
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news